Report of seizure induced by intermittent theta burst stimulation

Ferguson, Jonathan; Huffman, Sonya Kostova; Parmar, Sonali; Blankenship, Aidan; Brown, Truman R.; George, Mark S.

doi:10.1016/j.brs.2022.09.007

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though at least one case of liTBS-induced seizure has been reported, favourable seizure safety data exists on more intensive rTMS approaches. [18][19][20] The absence of seizures in our sample additionally supports the rarity of this severe side effect under the bsTBS configuration and extends the available side effect data of bsTBS to include younger age groups. That no reliable pre-treatment predictors were identified for depressive symptom response suggests that larger studies and/or updated statistical or machine learning methods would be needed to identify depressive symptom response predictors.…”

Section: Discussionsupporting

confidence: 81%

Unilateral and Bilateral Theta Burst Stimulation for Treatment-Resistant Depression: Follow up on a Naturalistic Observation Study

Elnazali,

Veerakumar,

Blair

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Theta burst stimulation (TBS) is a novel and faster modality of transcranial magnetic stimulation, which is showing promise as a treatment-resistant depression (TRD) treatment. Though TBS can be applied unilaterally or bilaterally, few studies have compared the effectiveness of both approaches in a naturalistic clinical sample. Objectives: In this retrospective chart review, we aimed to: (1) replicate previous bilateral sequential TBS effectiveness in a larger cohort of patients at a single centre, (2) present treatment outcome data between unilateral and bilateral TBS approaches, (3) investigate baseline factors associated with our observed outcomes, and (4) examine the sustainability of response, with follow-up data up to 6 months from patients. Methods: We included 161 patients who received TBS (unilateral: n = 64 (40%), 45.55 ± 14.25 years old, 55% females; bilateral: n = 97 (60%), 47.67 ± 15.11 years old, 58% females). Results: Firstly, we observed 47% response and 34% remission in the bilateral group, replicating findings from a smaller naturalistic study from our group; patients receiving unilateral TBS displayed 36% response and 26% remission, with no significant differences found between unilateral and bilateral TBS in remission and response rates. Secondly, bilaterally stimulated patients needed fewer treatments than those stimulated unilaterally (27 vs 29 on average respectively, t [159] = 3.31, p = .001), and had significantly lower anxiety symptoms post treatment (GAD-7) relative to patients receiving unilateral stimulation, F (1,148) = 3.95, p =0.049. Thirdly, no baseline factors were found to predict treatment outcomes. Lastly, after six months, 69% of patients who met the response criteria did not require additional treatment or a change in medication. Conclusions: Our findings support the efficacy and tolerability of TBS in TRD and indicate that bilateral TBS may have a superior anxiolytic effect and offer a slightly faster time to response.

show abstract

Section: Discussionsupporting

confidence: 81%